Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;1(3):276-290.
doi: 10.1038/s43018-020-0043-5. Epub 2020 Mar 20.

Circulating tumor DNA and liquid biopsy in oncology

David W Cescon  1 , Scott V Bratman  2 , Steven M Chan  1 , Lillian L Siu  3
Affiliations
Review

Circulating tumor DNA and liquid biopsy in oncology

David W Cescon et al. Nat Cancer. 2020 Mar.

Abstract

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the capabilities of this technology as a diagnostic test. The full potential of ctDNA liquid biopsy in the diagnosis, characterization and management of solid and hematological malignancies will be uncovered through interventional clinical trials evaluating clinical utility. In this Review, we discuss the current landscape of ctDNA liquid-biopsy applications across the cancer continuum and highlight opportunities for clinical investigation.

PubMed Disclaimer

References

    1. La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587–596 (2011). - PubMed
    1. Basik, M. et al. Biopsies: next-generation biospecimens for tailoring therapy. Nat. Rev. Clin. Oncol. 10, 437–450 (2013). - PubMed
    1. Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017). - PubMed
    1. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008). - PubMed
    1. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009). - PubMed